Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ceilidh Stapelkamp"'
Autor:
Ash Bullement, Ceilidh Stapelkamp, Amerah Amin, A. Willis, Chris P Pescott, Paul Nathan, Anthony J. Hatswell, C. Lilley, Murtuza Bharmal
Publikováno v:
PharmacoEconomics Open
Background\ud \ud Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f1df0f5b41daafa9a78d4e52cb54ac7
https://doi.org/10.1007/s41669-018-0115-y
https://doi.org/10.1007/s41669-018-0115-y
Autor:
Sylvie Pfersch, Peter Mohr, Sorrel Wolowacz, Florent Grange, Rainer Ehness, Lori McLeod, Ilias Kontoudis, Ceilidh Stapelkamp, Obukohwo Siakpere, Mark Harries, L Benjamin, James A. Kaye, Janina Barth
Publikováno v:
Melanoma Research. 27:607-618
The aim of this study was to estimate the cost-of-illness associated with completely resected stage IIIB/IIIC melanoma with macroscopic lymph node involvement, overall and by disease phase, in France, Germany and the UK. This retrospective observatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159c9269f9a12fa029f745f2c3e0962f
https://doi.org/10.1097/cmr.0000000000000372
https://doi.org/10.1097/cmr.0000000000000372
Autor:
Katja Vouk, Ursula Benter, L Benjamin, A Marocco, Ceilidh Stapelkamp, Mayur M. Amonkar, Sylvie Pfersch
Publikováno v:
Journal of Medical Economics. 19:900-912
Objective: To estimate per-event cost and economic burden associated with managing the most common and/or severe metastatic melanoma (MM) treatment-related adverse events (AEs) in Australia, France, Germany, Italy, and the UK. Methods: AEs associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6b9d6e8c72e2b1939a3e9c290f6dd1
https://doi.org/10.1080/13696998.2016.1184155
https://doi.org/10.1080/13696998.2016.1184155
Autor:
C. Lilley, Murtuza Bharmal, A. Willis, Ash Bullement, Ceilidh Stapelkamp, Anthony J. Hatswell, Amerah Amin, Chris P Pescott
Publikováno v:
Value in Health. 21:S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67f4733e6c3c14c5d98e23f502b68c6b
https://doi.org/10.1016/j.jval.2018.09.062
https://doi.org/10.1016/j.jval.2018.09.062
Autor:
Anthony J. Hatswell, A. Willis, Ceilidh Stapelkamp, Amerah Amin, C. Lilley, Murtuza Bharmal, Sandra P. D'Angelo, Ash Bullement
Publikováno v:
Journal of Clinical Oncology. 36:e21620-e21620
e21620Background: Data from the JAVELIN Merkel 200 (JM 200) trial of avelumab in mMCC with a minimum follow-up of 18 mo for 88 pts who had received prior chemotherapy demonstrated robust survival e...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ed09812998974273d69173529a8bb30
https://doi.org/10.1200/jco.2018.36.15_suppl.e21620
https://doi.org/10.1200/jco.2018.36.15_suppl.e21620
Publikováno v:
Melanoma research. 25(6)
Patients with BRAF V600E mutation-positive melanoma who were assigned to 150 mg dabrafenib twice daily combined with 2 mg trametinib once daily in a phase I/II study showed a median overall survival (OS) of 23.8 months, compared with 20.2 months for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c575145def62a2b9037f1df5703e436
https://pubmed.ncbi.nlm.nih.gov/26340744
https://pubmed.ncbi.nlm.nih.gov/26340744
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 19(5)
Objectives To evaluate the cost-effectiveness of eltrombopag compared with romiplostim to be used in the treatment of chronic immune thrombocytopenia in patients in England and Wales who are splenectomized or ineligible for splenectomy and are refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60eb12f62c089e0760e598faf453a9bc
https://pubmed.ncbi.nlm.nih.gov/27565278
https://pubmed.ncbi.nlm.nih.gov/27565278
Background. Patients with previously untreated BRAF V600E mutation-positive melanoma in BREAK-3 showed a median overall survival (OS) of 18.2 months for dabrafenib versus 15.6 months for dacarbazine (hazard ratio [HR], 0.76; 95% confidence interval,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61cf09daf22882a44978938da4b9947a
https://europepmc.org/articles/PMC4492231/
https://europepmc.org/articles/PMC4492231/
Autor:
Suzanne Swann, Amit Ahuja, Ceilidh Stapelkamp, Cheena Rana, Mayur M. Amonkar, Kunal Srivastava, Michelle Casey
Publikováno v:
Journal of Clinical & Experimental Dermatology Research.
Objectives: A systematic literature review was undertaken with quantitative analysis, including meta-analysis and Bucher-adjusted indirect treatment comparisons (ITCs), to evaluate efficacy, safety, and tolerability of dabrafenib and trametinib monot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b8b869497da590ef38f48eab67ae0e6
https://doi.org/10.4172/2155-9554.10000294
https://doi.org/10.4172/2155-9554.10000294
Autor:
L Benjamin, Florent Grange, Rainer Ehness, James A. Kaye, Sylvie Pfersch, Janina Barth, Sorrel Wolowacz, Mark Harries, Lori McLeod, Ilias Kontoudis, Ceilidh Stapelkamp, Peter Mohr, Obukohwo Siakpere
Publikováno v:
International Journal of Clinical Practice
SummaryAim Real-world data on treatment patterns/outcomes in patients with advanced melanoma, while scarce, are useful for health technology assessments that govern patient access in many countries. We collected retrospective data on treatment patter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6538f5188633d08a3f94010074fbad6
https://doi.org/10.1111/ijcp.12946
https://doi.org/10.1111/ijcp.12946